These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

910 related items for PubMed ID: 29750868

  • 1. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    Mol Pharm; 2018 Jul 02; 15(7):2742-2753. PubMed ID: 29750868
    [Abstract] [Full Text] [Related]

  • 2. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.
    Mol Pharm; 2018 Feb 05; 15(2):472-485. PubMed ID: 29283581
    [Abstract] [Full Text] [Related]

  • 3. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.
    Clin Cancer Res; 2011 Feb 15; 17(4):783-91. PubMed ID: 21097693
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ.
    Gynecol Oncol; 2020 Dec 15; 159(3):869-876. PubMed ID: 33032822
    [Abstract] [Full Text] [Related]

  • 5. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
    Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Domènech-Vivó J, García-Galea E, Moles-Fernández A, Pedretti F, Domènech H, Rodríguez O, Guzmán M, Arenas EJ, Verdaguer H, Calero-Nieto FJ, Talbot S, Tobalina L, Leo E, Lau A, Nuciforo P, Dienstmann R, Macarulla T, Arribas J, Díez O, Gutiérrez-Enríquez S, Forment JV, O'Connor MJ, Albertella M, Balmaña J, Serra V.
    Genome Med; 2024 Aug 26; 16(1):107. PubMed ID: 39187844
    [Abstract] [Full Text] [Related]

  • 6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 26; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M, Chhina J, Mert I, Taylor M, Dar S, Al-Wahab Z, Ali-Fehmi R, Buekers T, Munkarah AR, Rattan R.
    Gynecol Oncol; 2016 Aug 26; 142(2):323-31. PubMed ID: 27282964
    [Abstract] [Full Text] [Related]

  • 8. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    Clin Cancer Res; 2019 Oct 15; 25(20):6127-6140. PubMed ID: 31409614
    [Abstract] [Full Text] [Related]

  • 9. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC.
    Trials; 2016 Jun 21; 17(1):293. PubMed ID: 27323902
    [Abstract] [Full Text] [Related]

  • 10. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    Gynecol Oncol; 2018 Sep 21; 150(3):534-544. PubMed ID: 30025822
    [Abstract] [Full Text] [Related]

  • 11. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Sep 21; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 12. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.
    Gynecol Oncol; 2016 Sep 21; 142(3):548-56. PubMed ID: 27426307
    [Abstract] [Full Text] [Related]

  • 13. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.
    BMC Cancer; 2016 Jul 27; 16():550. PubMed ID: 27465688
    [Abstract] [Full Text] [Related]

  • 14. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    J Ovarian Res; 2019 Jan 28; 12(1):9. PubMed ID: 30691488
    [Abstract] [Full Text] [Related]

  • 15. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D.
    Gynecol Oncol; 2021 Jul 28; 162(1):163-172. PubMed ID: 33867143
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC, Weitzel JN, O'Connor TR.
    Mol Cancer Ther; 2012 Sep 28; 11(9):1948-58. PubMed ID: 22778154
    [Abstract] [Full Text] [Related]

  • 17. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS, Eskander RN, Monk BJ.
    Clin Cancer Res; 2015 Sep 01; 21(17):3829-35. PubMed ID: 26169965
    [Abstract] [Full Text] [Related]

  • 18. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.
    PLoS One; 2018 Sep 01; 13(11):e0207399. PubMed ID: 30444904
    [Abstract] [Full Text] [Related]

  • 19. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug 01; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

  • 20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW, Tewari KS.
    Curr Treat Options Oncol; 2016 Mar 01; 17(3):12. PubMed ID: 26931795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.